clinical trial · NCT04722523
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Head and Neck CancerHead CancerHead Cancer NeckNeck CancerHead and Neck Squamous Cell CarcinomaHNSCCCisplatinCarboplatinDocetaxelCetuximabCemiplimabSurgical Resection of Primary +/- Neck DissectionPost-operative radiation therapyPaclitaxel
brief summary
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
started
Jan 20, 2021
primary completion
Jun 20, 2027
completion
Jun 20, 2027
last updated
Jul 21, 2026
official title
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol